CS Paper Radar

DNA Methylation Profiling in Melanoma: From Lesion Classification to Therapeutic Stratification

Jana T. Winterstein, Lukas Heinlein, Günter Raddatz, Carina Nogueira Garcia, Sarah Haggenmüller, Christoph Wies, Lucas Schneider, Annemarie Hoffsommer, Tim J. Zeuner, Friedegund Meier, Sarah Hobelsberger, Frank F. Gellrich, Mildred Sergon, Axel Hauschild, Lucie Heinzerling, Justin G. Schlager, Kamran Ghoreschi, Max Schlaak, Franz J. Hilke, Carola Berking, Markus V. Heppt, Michael Erdmann, Sebastian Haferkamp, Konstantin Drexler, Dirk Schadendorf, Wiebke Sondermann, Matthias Goebeler, Bastian Schilling, Daniel B. Lipka, Stefan Fröhling, Felix Sahm, Jakob N. Kather, Yuri Tolkach, Jochen S. Utikal, Benjamin Izar, Yevgeniy R. Semenov, Titus J. Brinker

cs.LG q-bio.GN ·submitted 2026-08-19 14:53 UTC · v1

Abstract

DNA methylation provides a stable record of cellular identity, capturing epigenetic programs that distinguish specialized cell states despite a shared genome. Because malignant transformation and tumour progression are accompanied by extensive epigenetic remodeling, we hypothesized that the methylome of melanocytic lesions contains biologically and clinically relevant information for both diagnosis and disease progression. In a cohort of 1,001 tissue samples prospectively collected across eight German university hospitals profiled using Illumina Infinium MethylationEPIC arrays, we compared machine-learning models based on selected Cytosine phosphate Guanine (CpG) methylation sites with models incorporating biology-guided features, including epigenetic age acceleration, cell type composition and copy-number variation burden. In an external test set, the best diagnostic classifier was CpG-based and distinguished melanocytic nevi, noninvasive melanoma and invasive melanoma with a macro-averaged area under the receiver operating characteristic curve of 0.919 (95% CI: 0.878 to 0.952). Notably, across CpGs most strongly hyper- and hypomethylated between NV and IM, NIM showed an intermediate methylation profile, providing a molecular correlate of its diagnostic complexity. The best model for clinically relevant treatment group prediction, with AJCC stages grouped according to guideline-based management recommendations, relied on biology-guided features and achieved a macro-averaged mean absolute error of 0.627 (95% CI: 0.477 to 0.808). Together, these findings demonstrate that methylation-based models can capture both diagnostic identity and clinically relevant disease stratification, supporting DNA methylation as a promising biomarker for further validation and potential clinical translation.

Closest papers

Nearest neighbours by meaning across the whole index.

Evaluating Single and Multi-Omics Based Explainable Artificial Intelligence (MOXAI) for Molecular Subclass Classification of Adult-Type Diffuse Gliomas

cs.CV cs.AI ·2026-09-26 ·Md Zahangir Alom, Quynh T. Tran, Breuer Alexandar, Brent A. Orr
similarity 0.64
Abstract · 8 pages, 6 figures

DNA methylation (DNAM) profiling has emerged as a powerful diagnostic tool for classifying brain and solid tumors. However, existing computational models typically analyze methylation and copy number variation (CNV) data separately, failing to capture the complementary information their integration could provide. Moreover, current classification models lack mechanisms for within-class risk assessment analogous to traditional tumor grading, and no established explainability method can attribute classification decisions to specific genomic loci. In this paper, we present MOXAI (Multi-Omics Based Explainable AI), a deep learning framework that integrates DNA methylation and copy number data from methylation arrays to classify molecular subtypes of adult-type diffuse gliomas, alongside single-modality variants for comparison. Using a cohort from The Cancer Genome Atlas (TCGA), we trained ResNet50, DINOv2, and Graph Attention Network (GAT) models on methylation data alone, copy number data alone, and combined multimodal data. We further developed explainable AI (XAI) methods based on class activation maps (CAMs) and gradient-weighted CAM (Grad-CAM) to identify the specific CpG sites, genes, and chromosomal regions most relevant to each classification decision. The multimodal model achieved up to 92.98% cross-validation accuracy, outperforming models trained on CNV data alone. DINOv2 showed the strongest generalization, reaching 94.25% accuracy (confidence >0.9) on independent validation sets. XAI results aligned with established molecular features of adult-type diffuse glioma subtypes, confirming the biological interpretability of the framework.

0.14

Enhancing Clinical Classifier Robustness with Deep Representation Learning Based OOD Detection on DNA Methylation Data

cs.AI q-bio.GNcs.LG ·2026-10-26 ·Md Zahangir Alom, Quynh T. Tran, Breuer Alexandar, Brent A. Orr
similarity 0.62
Abstract · 11 pages, 8 figures

DNA methylation (DNAM) array-based tumor classification is a powerful clinical diagnostic tool, but models trained on fixed reference cohorts can produce faulty predictions for tumor types not represented in the training distribution. We propose an end-to-end deep representation learning-based out-of-distribution (OOD) detection framework for DNAm array data. Deep neural network (DNN) classifiers were trained on public sarcoma (SARC) (GSE140686) and brain tumor (BT) (GSE90496) cohorts, and feature vectors were extracted from bottleneck layers. Five OOD methods, including 1dimension (1D)-Subspace Analysis (1D-SSA), K-Nearest Neighbors (KNN), Ridge Regression, Mahalanobis Distance (MD), and Sum of Squared Distances (SSD), were explored with 200 and 500-dimensional embeddings. Spectral discrepancy was used to discriminate in-distribution (IND) from OOD samples. Performance was measured via cross-validation, holdout samples, and an independent clinical dataset. 1D-SSA was the most effective approach. In the sarcoma-IND/brain tumor-OOD setting, the framework achieved an AUROC of 0.975 and True Negative Rate (TNR)@95TPR of 0.930, and an AUROC of 0.9569 and TNR@95TPR of 0.8660 for the brain tumor-IND/sarcoma-OOD setting. On the independent clinical test set, the method yielded a mean AUROC of 0.976, a DE of 0.032, an FPR@95TPR of 0.065, and a TNR@95TPR of 0.935. These results show deep representation-based OOD detection as a practical quality-control layer for clinical-grade methylation-based tumor classification systems.

0.27

Evidence-Driven Differential Diagnosis of Malignant Melanoma

eess.IV cs.AIcs.CVcs.LG ·2026-08-28 ·Naren Akash, Anirudh Kaushik, Jayanthi Sivaswamy
top venuecode/data similarity 0.58
Abstract

We present a modular and multi-level framework for the differential diagnosis of malignant melanoma. Our framework integrates contextual information and evidence at the lesion, patient, and population levels, enabling decision-making at each level. We introduce an anatomic-site aware masked transformer, which effectively models the patient context by considering all lesions in a patient, which can be variable in count, and their site of incidence. Additionally, we incorporate patient metadata via learnable demographics embeddings to capture population statistics. Through extensive experiments, we explore the influence of specific information on the decision-making process and examine the tradeoff in metrics when considering different types of information. Validation results using the SIIM-ISIC 2020 dataset indicate including the lesion context with location and metadata improves specificity by 17.15% and 7.14%, respectively, while enhancing balanced accuracy. The code is available at https://github.com/narenakash/meldd.

0.69

Benchmarking Machine-Learning Classifiers for Neoantigen Immunogenicity Prediction and the Limits of SHAP Interpretability

cs.AI cs.LG ·2026-10-31 ·Ramon Gonzalez
benchmark similarity 0.56
Abstract · 23 pages, 8 figures, 7 tables

Personalized cancer vaccines require prioritizing, among hundreds of candidate mutant peptides, the few that will induce a T-cell response. This study asks what general-purpose machine learning achieves on that task, and whether the features such models identify as important can be trusted. We make three contributions. The first is a benchmark of sixty models: twelve supervised classifier families, each in five configurations, evaluated on the Immunogenic Tumor Specific Neoantigen database (ITSNdb; 199 experimentally validated neoantigens, 129 immunogenic and 70 non-immunogenic). All sixty are compared under one stratified k-fold cross-validation protocol, in which the data used to choose a configuration are never the data used to score it. The second is an interpretability study that combines SHAP with feature ablation. The third is a shuffled-label control that tests whether a SHAP value has been earned. Two results follow, and both run against current practice. First, the classical linear models lead the ranking. The gradient-boosted ensembles and neural networks that dominate recent work bring no advantage. Second, SHAP can fail on high-cardinality categorical features. Ablation establishes the presenting HLA allele as the dominant input and the source gene as dispensable. SHAP reports the opposite, assigning 68.7% to 81.7% of its total value to the source gene in every model that gives each gene its own weight. Shuffling the gene labels at random among the peptides resolves the contradiction: the meaningless column earns the same SHAP value as the real one. That value measures only that ITSNdb contains 173 genes for 199 peptides. We therefore recommend that SHAP values for high-cardinality categorical annotations in cohorts of this size always be reported against such a shuffled-label control, and we describe one in full.

0.35

An Explainable and Scalable Hierarchical Tensor Framework for Integrating Multi-Omics and Digital Pathomics

cs.AI q-bio.GN ·2026-11-19 ·Ahmad Hussein, Ali Anaissi, Mukesh Prasad, Ali Braytee
similarity 0.53
Abstract

Background: Precision oncology requires integration of heterogeneous molecular and pathology data, yet many fusion models offer limited biologically grounded interpretability and struggle with missing modalities. Methods: We present Hierarchical Interpretable Tensor Fusion (HIT-Fuse), integrating six modalities: somatic copy number variation, DNA methylation, RNA sequencing, microRNA expression, RPPA protein abundance, and vision transformer-derived pathomics across four TCGA cohorts (glioma, lung adenocarcinoma, breast, and kidney cancer). Modality-specific autoencoders compress high-dimensional inputs, followed by two-stage CP tensor decomposition. Missing latent modalities are reconstructed using clinical covariates and observed omics to expand cohorts and retrain downstream models. A mathematical traceback mechanism enables global and local xAI attributions. Results: HIT-Fuse identifies distinct latent subgroups with significant survival stratification in glioma, breast, and kidney cohorts, both with complete and reconstructed modalities. Cohort expansion yields cohort-specific gains, including a 56.4% relative increase in weighted F1 for glioma. Biological validation against DepMap CRISPR screens, miRTarBase and RPPA annotations supports decoded drivers across all four cohorts. Essential gene rates range from 6.2% in glioma to 7.6% in lung cancer; example drivers include ANAPC11, SNRPD1, PLK1 and RPL14. Of decoded miRNAs, 71-92% have miRTarBase regulatory support, while 77-84% of selected genes are covered in DepMap. Conclusions: HIT-Fuse combines hierarchical tensor fusion, missing-modality reconstruction and traceable attributions to support interpretable multi-omics and digital pathology-based cancer prognosis across heterogeneous cohorts.

0.06

State-Aware Interaction MIL for Rare Joint Molecular Phenotype Prediction in Colorectal Cancer and Lung Adenocarcinoma

cs.CV ·2026-10-04 ·Dasari Naga Raju, Tripti Bameta
published similarity 0.53
Abstract · Accepted at the NeurIPS 2026 Workshop on AI at Scale for Clinical Impact (ASCI): Cancer Pathology Foundation Models

Joint molecular phenotype prediction is complicated by small joint-positive populations and overlapping histological features across alternative molecular states. Existing computational pathology approaches typically predict biomarkers independently or formulate the joint-positive phenotype as a binary endpoint. Independent prediction does not model interactions between biomarker-specific histological representations, whereas binary joint prediction collapses the double-negative and two single-positive configurations into a single negative class. We propose State-Aware Interaction MIL, a weakly supervised method that preserves biomarker-specific histological representations, models their interaction, and supervises the complete four-state molecular configuration. We evaluate the proposed approach for joint BRAF+/MSI+ prediction in colorectal cancer and EGFR+/TP53+ prediction in lung adenocarcinoma using frozen UNI2-h and CONCH pathology foundation-model representations. With UNI2-h, State-Aware Interaction MIL achieved an average precision of 0.5566 in colorectal cancer (joint-positive prevalence 6.8%) compared with 0.5161 for NaiveMTL, and 0.2784 in lung adenocarcinoma (joint-positive prevalence 8.6%) compared with 0.2525 for IndependentPair. With CONCH, State-Aware achieved an average precision of 0.4410 compared with 0.3932 for DirectJoint in colorectal cancer and 0.1659 compared with 0.1226 for DirectJoint in lung adenocarcinoma. These results indicate that pathology foundation-model representations contain predictive information for rare joint molecular phenotypes and that preserving biomarker-specific representations within a structured molecular-state formulation can improve prediction of these phenotypes from histopathology.

0.31

Tensor-based Fusion of Multi-modal Data for Predicting Cancer Risk Levels

cs.LG q-bio.QM ·2026-10-09 ·Ali Anaissi, Yuanzhe Jia, Qishun Peng, Weidong Huang, Ali Braytee +1 more
similarity 0.52
Abstract

Cancer diagnosis and treatment increasingly rely on multi-modal diagnostic technologies that generate high-dimensional datasets. Although these datasets are rich in pathological information, they pose considerable challenges in interpretation, dimensionality reduction, and clinical applicability. Conventional machine learning approaches often fail to extract meaningful cross-modal features, thereby limiting predictive accuracy in patient risk stratification. To address these limitations, this paper proposes an unsupervised machine learning framework that integrates feature extraction, tensor decomposition, and clustering to improve cancer risk prediction. The framework employs tensor decomposition to fuse heterogeneous genomic and clinical data, enabling the extraction of latent, biologically meaningful features that outperform unimodal feature sets. Multiple feature extraction strategies are investigated, and the resulting features are subsequently clustered using a range of clustering algorithms. Comparative evaluations based on internal and external metrics are then used to identify the most effective configurations. The framework is validated on LinkedOmics data comprising 11,158 patients across 32 cancer types. For patient risk stratification, clinically relevant attributes such as tumor purity, pathological stage, and survival outcomes serve as ground-truth indicators. Experimental results demonstrate the superiority of tSVD+GMM, which consistently outperforms other configurations across clinical benchmarks.

0.34

Gaussian Meta-Space Augmentation for Stacking Ensembles in Multimodal IPMN Risk Stratification

cs.CV cs.LG ·2026-08-11 ·Max A. Nelson, Eminenur Sen Tasci, Zhixiang Wang, Zongwei Zhou, Halil Ertugrul Aktas +10 more
published similarity 0.52
Abstract · Accepted at the International Workshop on Machine Learning in Medical Imaging (MLMI 2026), held in conjunction with MICCAI 2026. This is the…

Pancreatic cancer is among the most lethal malignancies; risk stratification of intraductal papillary mucinous neoplasms (IPMNs) offers a crucial opportunity for early intervention but typically requires invasive tissue biopsy. Dominant vision-based approaches, including radiomics and deep learning, provide promising but initially separate discrimination opportunities. Similarly, multisequence MRI (T1W/T2W) and anatomically decomposed (head, body and tail) analysis of the pancreas provide additional and potentially complementary signals. Effective fusion of this information is crucial in ordinal IPMN dysplasia risk prediction and can be accomplished via a meticulously regularized and calibrated ensemble stacking combiner. We present cUPMI, a class-conditional Gaussian augmentation of a combiner's log-probability meta-features, and test it on various prediction paradigms. In our multi-center analysis, we find cUPMI adds limited value to properly regularized L2-logistic binary classification stacks, but consistently regularizes higher-capacity tree combiners in the binary and radiomics-only setting (RF +0.015 and XGBoost +0.024 binary AUC, positive in all seeds). Its cleanest ordinal benefit appears for XGBoost on an 8-stream radiomics task (3-class no < low < high, +0.022 QWK in all seeds). Separately, fold-locked fusion of radiomics and 2.5D CNN streams yields the strongest overall model, an RF stack reaching QWK 0.595 (95% CI [0.54, 0.64]) and binary AUC 0.839, surpassing radiomics, 2.5D ResNet, and 3D DenseNet-121 baselines.

0.26